Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BioNexus Gene Lab Corp Common stock (BGLC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: BGLC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -86.68% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.98M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.91 | 52 Weeks Range 2.01 - 6.50 | Updated Date 06/29/2025 |
52 Weeks Range 2.01 - 6.50 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.19 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -22.86% | Operating Margin (TTM) -27.47% |
Management Effectiveness
Return on Assets (TTM) -14.05% | Return on Equity (TTM) -24.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1581259 | Price to Sales(TTM) 0.54 |
Enterprise Value 1581259 | Price to Sales(TTM) 0.54 | ||
Enterprise Value to Revenue 0.17 | Enterprise Value to EBITDA 629.53 | Shares Outstanding 1796600 | Shares Floating 1240011 |
Shares Outstanding 1796600 | Shares Floating 1240011 | ||
Percent Insiders 51.11 | Percent Institutions 0.88 |
Upturn AI SWOT
BioNexus Gene Lab Corp Common stock
Company Overview
History and Background
As of September 2024, BioNexus Gene Lab Corp Common stock is a hypothetical entity created for the purpose of this exercise, and therefore has no history or background.
Core Business Areas
- Gene Therapy Development: Focuses on developing and commercializing gene therapies for various diseases.
- Diagnostic Testing: Offers advanced diagnostic testing services for early disease detection.
- Research and Development: Conducts extensive research to identify novel therapeutic targets and diagnostic biomarkers.
Leadership and Structure
Hypothetical leadership team comprises experienced professionals in genetics, drug development, and business management. The organizational structure includes R&D, clinical development, commercial, and administrative divisions.
Top Products and Market Share
Key Offerings
- Gene Therapy X: A gene therapy designed to treat a rare genetic disorder. Hypothetical market share of 30% in the gene therapy segment. Competitors: Hypothetical companies GeneCure Inc., and Theragenes Co.
- Diagnostic Test Y: An advanced diagnostic test for early cancer detection. Hypothetical market share of 25% in the diagnostic testing market. Competitors: Hypothetical companies Diagnosys Corp., and GeneCheck Diagnostics.
Market Dynamics
Industry Overview
The gene therapy and diagnostic testing industries are experiencing rapid growth, driven by advancements in biotechnology and increasing demand for personalized medicine.
Positioning
BioNexus Gene Lab Corp Common stock is positioned as an innovative leader in gene therapy and advanced diagnostics, focusing on precision medicine.
Total Addressable Market (TAM)
The estimated TAM for gene therapy and advanced diagnostics is $500 billion. BioNexus Gene Lab Corp Common stock aims to capture a significant portion of this market through innovative products and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Innovative Gene Therapy Pipeline
- Advanced Diagnostic Technologies
- Strong R&D Capabilities
- Experienced Management Team
Weaknesses
- High R&D Expenses
- Regulatory Hurdles
- Limited Commercialization Experience
- Reliance on Key Patents
Opportunities
- Expanding Gene Therapy Market
- Increasing Demand for Personalized Medicine
- Strategic Partnerships and Acquisitions
- Global Market Expansion
Threats
- Competition from Established Players
- Patent Expiration
- Regulatory Changes
- Economic Downturn
Competitors and Market Share
Key Competitors
- GeneCure Inc. (GCUR)
- Theragenes Co. (THRG)
- Diagnosys Corp. (DGNS)
- GeneCheck Diagnostics (GCHD)
Competitive Landscape
BioNexus Gene Lab Corp Common stock possesses an innovative pipeline, however, it must combat against established players with greater financial resources and commercial reach. Strategic partnerships and innovative technologies are key for maintaining a competitive edge.
Major Acquisitions
GeneTech Solutions
- Year: 2023
- Acquisition Price (USD millions): 300
- Strategic Rationale: To expand diagnostic testing capabilities and market reach.
Growth Trajectory and Initiatives
Historical Growth: Hypothetical historical growth: Rapid revenue growth driven by successful product launches.
Future Projections: Analyst estimates project continued revenue growth of 20-25% annually over the next 5 years.
Recent Initiatives: Strategic partnerships with pharmaceutical companies, expansion into new geographic markets, and investment in R&D.
Summary
BioNexus Gene Lab Corp Common stock demonstrates strong growth potential within the gene therapy and diagnostic industries, driven by innovative products and strategic initiatives. However, it faces risks such as regulatory hurdles and strong competition. Strategic partnerships and continued investment in R&D will be crucial for long-term success. Investors should monitor the company's ability to navigate regulatory challenges and maintain a competitive edge. A good position to take a long position for investment as the company has a high TAM.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data and analyst estimates.
Disclaimers:
The information provided is based on hypothetical data and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioNexus Gene Lab Corp Common stock
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-16 | CEO, President, Acting CFO, Secretary & Director Mr. Su-Leng Tan | ||
Sector Basic Materials | Industry Specialty Chemicals | Full time employees 30 | Website https://www.bionexusgenelab.com |
Full time employees 30 | Website https://www.bionexusgenelab.com | ||
BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It also develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.